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Protein aggregationIn patients with Alzheimer's disease, the microtubule-associated protein tau is found aggregated into
paired helical ﬁlaments (PHFs) in neuroﬁbrillary deposits. In solution, tau is intrinsically unstructured.
However, the tubulin binding domain consisting of three or four 31–32 amino acid repeat regions exhibits
both helical and β-structure propensity and makes up the proteolysis resistant core of PHFs. Here, we
studied the structure and dynamics of the three-repeat domain of tau (i.e. K19) when bound to
membranes consisting of a phosphatidylcholine and phosphatidylserine mixture or phosphatidylserine
alone. Tau K19 binds to phospholipid vesicles with submicromolar afﬁnity as measured by ﬂuorescence
spectroscopy. The interaction is driven by electrostatic forces between the positively charged protein and
the phospholipid head groups. The structure of the membrane-bound state of K19 was studied using CD
spectroscopy and solid-state magic-angle spinning NMR spectroscopy. To this end, the protein was
selectively 13C-labeled at all valine and leucine residues. Isotropic chemical shift values of tau K19 were
consistent with a β-structure. In addition, motionally averaged 1H–13C dipolar couplings indicated a high
rigidity of the protein backbone. The structure formation of K19 was also shown to depend on the charge
density of the membrane. Phosphatidylserine membranes induced a gain in the α-helix structure along
with an immersion of K19 into the phospholipid bilayer as indicated by a reduction of the lipid chain 2H
NMR order parameter. Our results provide structural insights into the membrane-bound state of tau K19
and support a potential role of phospholipid membranes in mediating the physiological and pathological
functions of tau.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The occurrence of ﬁbrillar protein aggregates is a hallmark in
Alzheimer's disease (AD) and related dementias [1,2]. Extracellular
amyloid plaques arise from the β-amyloid peptide (Aβ) [3] and
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l rights reserved.composed of regular ﬁbrils of the microtubule-associated protein tau
[4,5]. Because ﬁbrillar lesions correlate with both neuronal cell loss
[6] and cognitive decline [7] they are useful markers of neurodegen-
eration in AD [8]. Thus, there has been much interest in understand-
ing the mechanisms of protein ﬁbrillization and the cellular factors
having an impact on it. In the case of the tau protein, an increase in
the cytosolic concentration of unbound, hyperphosphorylated tau has
been considered the pivotal event, which in its consequence can lead
to protein aggregation [9,10]. However, tau has also been shown to
ﬁbrillize in vitro by the addition of polyanionic substances such as
glycosaminoglycans (heparin, dextran sulfate) [11], polyglutamate
[12], RNA [13], or by addition of fatty acids [14,15] and anionic
micelles [16]. Currently, there is no genetic component known for tau
aggregation in AD, but several mutations have been linked to the
related neurodegenerative syndrome, frontotemporal dementia and
Parkinsonism linked to chromosome 17 (FTDP-17) [17–19]. Most
FTDP-17 mutations have been identiﬁed to be located near the C-
terminal microtubule binding repeat regions, suggesting an impor-
tant role of those regions in the formation of tau paired helical
ﬁlaments (PHFs) [20]. Although tau has no a priori amyloidogenic
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the huntingtin protein (for reviews see [21,22]), short patches at the
beginning of the second (275VQIINK280) and third (306VQIVYK311)
repeats have been identiﬁed as aggregation motifs of tau [23]. They
have been found to form the protease resistant core of PHFs by
interacting as alternately stacked cross β-sheets [24–26]. In
contrast, the N-terminal projection domain and proline-rich region
of tau remain disordered and form a fuzzy coat surrounding the
ﬁlament core [20,27]. However, apart from characterizing the
structure of tau in its soluble and aggregated state, the exact
mechanism of tau ﬁbrillization and the structural transitions
occurring along the aggregation process are still unknown. It is
proposed that beginning from small, non-ﬁbrillar intermediates
with no observable cross β-structure and no sensitivity to thioﬂavin
T (ThT) or congo red, tau molecules can order into either straight
ﬁlaments (SFs) or more typically into paired helical ﬁlaments
(PHFs) [28]. Similarly to Aβ ﬁbrils, tau PHFs are believed to consist
of protoﬁbrils as well, however, their exact topology is still a matter
of debate [29].
Soluble tau belongs to the class of natively unfolded proteins and
thus has not been amenable to structure analysis by x-ray
crystallography. On the other hand, nuclear magnetic resonance
(NMR) spectroscopy is often hampered by a dramatic signal overlap
due to the lack of ordered structure. That is why NMR studies have
predominantly been performed with fragments of tau containing
e.g. only the repeat domain (K19 or K18) [30–33]. However, the full
resonance assignment and residual secondary structure determina-
tion for the longest tau isoform (441 residue tau) have been
achieved recently [34]. Those experiments revealed that tau
preferentially populates β-structure in the regions between repeats
R2, R3 and R4 [30,31], but a weak helical [31] or much lower β-
structure [30] propensity within the repeats themselves has been
shown. A stable α-helix conformation in those regions was
observed in the presence of anionic micelles, suggesting a structural
reorganization of the protein in a membrane-like environment [33].
It is known from other amyloidogenic peptides that they often
adopt a more well-ordered structure upon binding to biological
membranes [35]. In that case, studies of membrane–protein in-
teractions could also provide important mechanistic insights into
the amyloidogenic pathways of the aggregation-prone peptides (for
reviews see [36–38]). These ﬁndings propose a common mode, by
which ﬁbrillarized peptides and proteins could execute their cell
toxic potential, i.e. by a perturbation of the membrane integrity
[39–42]. A similar role of membranes in both tau aggregation and
tau toxicity could be reasoned, too. Interestingly, tau is found
attached to the neuronal cell membrane both in its non-pathologic
state [43–45] and in form of PHFs in cells from AD brains [46]. Tau
aggregates occur in complex with the inner cell cortex and with cell
organelles already at early stages of the disease [47]. Although,
free fatty acids [14,15] and anionic phospholipids [16] were shown
to induce ﬁbrillization of tau, binding to cellular membranes
with multiple phospholipid components has not been analyzed
yet. Furthermore, possible conformational changes of tau upon
membrane binding and their role during the aggregation process
have not been examined either.
Here, we report a structural study on membrane-bound tau K19.
We investigated the three-repeat microtubule binding domain of tau,
i.e. K19, in complex with phospholipid model membranes consisting
of phosphatidylcholine and phosphatidylserine. Membrane–protein
interactions and protein secondary structure were both studied using
methods of ﬂuorescence, CD, and solid-state NMR spectroscopy. The
latter is the method of choice that can provide high resolution
structural information for proteins in their complex membrane
environment [48,49]. We hypothesize that the membrane-bound
conformation may be important for both the normal function of tau
and for its pathogenicity.2. Materials and methods
2.1. Materials
The lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine (POPS),
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-
d54-sn-glycero-3-phosphocholine (DMPC-d54), 1,2-dimyristoyl-d54-
sn-glycero-3-phosphocholine-d13 (DMPC-d67), 1,2-dimyristoyl-sn-
glycero-3-phosphoserine (DMPS) and 1,2-dimyristoyl-d54-sn-glycero-
3-phosphoserine (DMPS-d54) were purchased from Avanti Polar Lipids,
Inc. (Alabaster, AL, USA) and were used without further puriﬁcation.
Sodium dodecyl-d25 sulfate and 13C-labeled formaldehyde were
purchased from Cambridge Isotope Laboratories Inc. (Andova, MA,
USA). 1,2-13C2-leucine and U-13C5, 15N-valine were purchased from
Cambridge Isotope Laboratories, Inc. Further reagents and solventswere
obtained from Carl Roth® GmbH (Karlsruhe, Germany) and Sigma
Aldrich® Chemie GmbH (Steinheim, Germany).
2.2. Methods
2.2.1. Protein expression and puriﬁcation
Recombinant protein was expressed in Escherichia coli cells trans-
fected with a pET vector construct containing the DNA sequence of tau
K19 under control of the T7 promoter (a kind gift fromDr. Peter Lansbury
and Dr. Kenneth Kosik, Harvard Medical School). Tau K19 is a three-
repeat microtubule-binding fragment, which includes the ﬁrst, third, and
fourth microtubule-binding repeats of tau, similarly to the naturally
occurring three-repeat tau isoforms. Tau K19 consists of the residues
244–274 followed by the residues 306–372 of the sequence of the longest
human tau isoform, htau40. For selective labeling, 1,2-13C2-leucine and
U-13C5, 15N-valine (both purchased from Cambridge Isotope Laborato-
ries, Inc.) were added to 15N minimal media 30 min after induction with
IPTG. Puriﬁcation followed the same protocol as described before [31].
2.2.2. Reductive lysine 13C methylation
Reductive methylation of tau K19 was performed as described by
Means and Feeney [50]. Brieﬂy, 20 μl of 1 M borane–ammonia
complex (NH3.BH3) and 40 µL of 1 M 13C-formaldehyde were added
to 1 mL of 0.5 mg/mL tau K19 in 200 mM CHES, pH 10.2 and the
reaction was incubated for 2 h while stirring at room temperature.
The addition of borane–ammonia complex and 13C-formaldehyde
was repeated and the mixture was incubated for another 2 h. After
addition of another 10 µL of borane–ammonia complex the solution
was incubated at room temperature with stirring overnight. The
reaction was stopped by adding glycine to 200 mM and undesired
reaction products and excess reagents were removed by dialysis
against 10 mM HEPES, 10 mM NaCl, pH 7.4 in the case of solid-state
NMR experiments or 10 mM Na2HPO4, 100 mM NaCl, pH 7.4 when
using tau K19 for solution NMR.
The extent of the methylation reaction was assayed using the
amino-reactive dye ﬂuorescamine and was shown to run to com-
pletion. As analyzed by matrix-assisted laser desorption ionization
(MALDI) mass spectrometry, lysine residues are mainly di-13C-
methylated resulting in an experimentally determined mass increase
of 542 for tau K19 (as compared to a calculated increase of 544 for 17
potential free amino groups of K19).
2.2.3. Sample preparation
Large unilamellar vesicles (LUVs) of POPC/POPS or DMPC/DMPS at
a molar ratio of 4:1 were formed by extrusion under nitrogen
pressure through a nucleopore polycarbonate membrane [51]. Small
unilamellar vesicles (SUVs) of DMPS or DMPC/DMPS were prepared
by sonication as described by Huang [52]. The lipid concentration
after extrusion or sonication was determined using a phosphorous
assay according to the procedure of Chen et al. [53].
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isotopically labeled tau K19 dissolved in buffer A (10 mM HEPES,
10 mM NaCl, pH 7.4) to obtain a lipid:protein molar ratio of 50:1.
Lipid bound tau K19 was separated from unbound protein by
ultracentrifugation for 5 h at 92,500×g and 4 °C. The pellet was
frozen in liquid nitrogen and lyophilized under a vacuum of
~0.1 mbar over night. Subsequently, the sample was rehydrated to
50 wt.% by adding water and equilibrated by freeze-thaw cycles,
stirring and gentle centrifugation. Finally, the sample was transferred
to a 4 mm MAS rotor equipped with a cylindrical Teﬂon insert pro-
viding a volume of 50 μL.
For static 2H and 31P NMR measurements, unlabeled tau K19 was
used. The samples were prepared in analogy to the NMR samples
with isotopically labeled tau K19.
2.2.4. Fluorescence measurements
The intrinsic ﬂuorescence of tau K19 was measured with an ISA
Jobin Yvon SPEX FluoroMax-2 spectroﬂuorometer (Jobin-Yvon,
Edison, NJ, USA). An excitation wavelength for tyrosine of 278 nm
was used. Spectra were recorded in the region of 290–410 nm and
were averaged to achieve an adequate signal to noise ratio. After
background correction, the spectra were ﬁtted to a log-normal
distribution [54]:
I λð Þ ¼ Imax exp −
ln2
ln2ρ
ln2 1þ
λ−λmaxð Þ ρ2−1
 
ρΓ
0
@
1
A
2
4
3
5; ð1Þ
where Imax is the intensity observed at the wavelength of maximum
intensity λmax and Γ is the full width of the spectrum at half-
maximum intensity Imax/2. The asymmetry of the distribution is
described by the parameter ρ. Nonlinear least-squares ﬁtting was
performed with Origin 6.0 (MicroCal. Inc., Northhampton, MA, USA)
to determine the intensity at constant wavelength, which was
obtained for Imax in the spectrum of complete membrane-bound tau
K19 (~303 nm). The fraction of membrane-bound protein was
calculated according to Ladokhin et al. [54]:
f b ¼
I−I0
I∞−I0
; ð2Þ
where fb denotes the membrane-bound fraction, I0 is the ﬂuorescence
intensity in the absence of lipid and I∞ is the ﬂuorescence intensity
that corresponds to complete binding. Intensity values were ﬁtted to
a one-site model [54]:
I L½ ð Þ ¼ I0 þ I∞−I0ð Þ
k L½ 
W½  þ k L½ 
 
; ð3Þ
with [L] the lipid concentration, k the mole-fraction (X) partition
coefﬁcient (k=Xbilayer/Xwater) and [W] the molar concentration of
water (55.5 M). The respective KD value for the transfer between the
membrane and water was determined from the mole-fraction parti-
tion coefﬁcient (KD=[W]/k) [55].
2.2.5. Leakage assay
Liposomes for the leakage assay were prepared as described under
Section 2.2.3. Buffer A contained additionally 60 mM of 6-
carboxyﬂuorescein. At this concentration, carboxyﬂuorescein is self-
quenched. The external ﬂuorophor was removed from the sample by
eluating 500 μL of the liposome solution trough a Sephadex G-50
column (GE Healthcare, Munich, Germany) with isotonic buffer
solution. The leakage experiments were performed on a FluoroMax-
2 spectroﬂuorometer (Jobin-Yvon, Edison, NJ, USA) at 25 °C. The
excitation wavelength was set at 485 nm and the ﬂuorescence signalwas detected at 515 nm. About 20 μL of the eluated liposomes was
diluted in 2.5 mL of isotonic buffer solution. The leakage of the
liposomes after adding the protein dilutes carboxyﬂuorescein below
10 mM and diminishes the ﬂuorophor self-quenching. The leakage
extentwas calculated by (I− I0)/(IT− I0), where I0 was the ﬂuorescence
intensity before adding the protein, I the observed ﬂuorescence signal
and IT the ﬂuorescence intensity after adding 2% (v/v) of Triton X-100.
2.2.6. Thioﬂavin T (ThT) assay
The formation of tau ﬁlaments was assayed using ThT ﬂuores-
cence, which is sensitive to amyloid deposits [56]. To this end, 6 μM of
tau K19 was added to 60 μM freshly ﬁltered ThT in buffer A and
incubated together with 600 μM of POPC/POPS or DMPC/DMPS LUVs
for several days at 37 °C and under continuous shaking. In this assay,
the presence of tau ﬁlaments is expected to result in a greatly
increased ThT ﬂuorescence at ~480 nm. The excitation wavelength
was set to 450 nm and spectra were recorded in the region of
460–520 nm. Control spectra were collected in the absence of protein
and in the presence of aggregated tau K19.
2.2.7. Circular dichroism (CD) spectroscopy
CD measurements were carried out on a Jasco J-715 CD
spectrophotometer. Tau K19 was prepared at different mixing ratios
with SUVs of DMPC/DMPS (mol% 80:20), DMPS, or with SDS in buffer
B (10 mM Na2HPO4, 10 mM NaCl, pH 7.4) and incubated for 30 min
prior to measurements. The protein concentration was 5 μM. CD
spectra were acquired in the region of 190–250 nmwith a scan rate of
50 nmmin−1, an increment of 1 nm and a response time of 1 s. Ten
spectra were averaged and background corrected (using the CD
spectra of buffer B or buffer B with SUVs). The secondary structure
content (α-helix, β-sheet, turn and random coil) was estimated
using three different deconvolution algorithms (CONTIN [57],
CDSSTR [58], and SELCON [59]) with reference dataset 7 from the
DICROWEB website.
2.2.8. DSC measurements
DSC measurements were performed with a Nano Differential
Scanning Calorimeter (TA Instruments, Lindon, UT). All samples were
degassed for at least 20 min prior injection and were heated from 5 °C
to 50 °C with a scan rate of 1 K/min relative to Buffer B containing
equal amounts of tau K19. DSC curves were baseline corrected
and the main phase transition enthalpy and temperature were
determined using the supplied software NanoAnalyze™ 2.0 (TA
Instruments, Lindon, UT).
2.2.9. Static solid-state NMR experiments
31P NMR experiments were carried out on a Bruker DRX300
spectrometer (Bruker BioSpin, Rheinstetten, Germany) operating at a
resonance frequency of 121.3 MHz for 31P using a 5 mm double
resonance probe. 31P NMR spectra were acquired using a Hahn echo
pulse sequence with a delay between pulses of 60 μs, a typical 90°
pulse length of 1.05–1.15 μs, a spectral width of 100 kHz and a recycle
delay of 2 s. Broadband 1H decoupling was applied during signal
acquisition. The temperature was 37 °C for all samples. To determine
the chemical shift anisotropy (Δσ), 31P spectra were simulated for
different Δσ values using Mathcad (Mathsoft, Inc., Cambridge, MA).
Due to the spherical distribution of the lipid molecules, powder
averaging was performed in 1° increments for the β Euler angle.
2H NMR spectra were recorded on a Bruker Avance 750 MHz
spectrometer at a resonance frequency of 115.3 MHz for 2H using a
probe with a 5 mm solenoid coil. 2H NMR spectra were accumulated
using a quadrupolar echo sequence with a 90° pulse length of
2.3–2.65 μs, a delay between pulses of 60 μs and a recycle delay of
0.5 s. The temperature was 37 °C for DMPC/DMPS (80:20 mol%) and
53 °C for DMPS, respectively. 2H NMR spectra were dePaked using the
Table 1
KD values for the titration of tau K19 with phospholipid vesicles depending on the
content of negatively charged phosphatidate (PA) or phosphatidylserine (PS) and on
the sodium concentration. The temperature was 25 °C except for DMPS, which was
measured at 37 °C.
Lipid composition (mol%) NaCl (mM) KD±S.D. (μM)
POPC 100 100 53.3±18.3
DMPS 100 100 0.22±0.04
POPC/POPA 80:20 100 7.97±4.34
POPC/POPS 80:20 100 0.93±0.08
DMPC/DMPS 80:20 100 2.40±0.18
POPC/POPS 80:20 10 0.42±0.06
DMPC/DMPS 80:20 10 0.38±0.10
Fig. 1. Change in the tyrosine ﬂuorescence intensity of 8 μM tau K19 as a function of the
titrated liposome concentration. Liposomes consisted of DMPC/DMPS (80/20 mol/mol)
in buffer A (10 mM HEPES, 100 mM NaCl, pH 7.4) at 25 °C. Error bars for each titration
point were obtained from the ﬁt of the ﬂuorescence spectrum to a log-normal
distribution by the Levenberg–Marquel algorithm, which is implemented in the Origin
6.0 software. The ﬂuorescence intensities were ﬁtted to a one site binding model.
Dissociation constants (KD) are given in Table 1.
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methylene group was calculated according to references [61,62].
2.2.10. Solution NMR experiments
Standard 1H–13C HSQC experiments with double inept transfer
and phase selection through echo/antiecho-TPPI gradient selection
[63] were recorded on a Bruker DRX600 spectrometer (Bruker,
Rheinstetten, Germany) using a 5 mm triple-inverse probe at 25 °C.
For each increment 24 scans were recorded with spectral widths of
6 kHz for 1H and 6 kHz for 13C as well as 128 data points in the 13C
dimension.
2.2.11. MAS NMR experiments
MAS NMR experiments were carried out on a Bruker Avance
750 MHz spectrometer at resonance frequencies of 749.9 MHz for 1H
and 188.6 MHz for 13C. A double resonance probe equipped with a
4 mm spinning module was used. Experiments were carried out at
37 °C for DMPC/DMPS and 53 °C for DMPS.
13C CP MAS spectra were acquired using a 4 μs long 1H 90°
excitation pulse and a cross-polarization (CP) contact time of 700 μs.
The radio frequency ﬁeld strength for heteronuclear two-pulse phase
modulation (TPPM) decoupling [64] was 62.5 MHz. Typical 90° pulse
lengths used in the following experiments were 4 μs for 1H and 6 μs
for 13C. The MAS frequency of all samples was 7 kHz. Chemical shifts
were referenced with respect to the 13CO signal of 13C-labeled glycine
at 176.45 ppm (relative to TMS) that was used as external standard.
Two-dimensional (2D) 13C–13C correlation spectra were obtained
using a proton-driven spin diffusion (PDSD) experiment [65]. Spin
diffusion periods of 100 and 500 ms were applied.
Two-dimensional 1H–13C heteronuclear correlation (HetCor) spec-
tra [66] were measured using the same parameters as for 13C CP MAS
spectra. 1H chemical shifts were referenced to the DMPC-glycerine-G2
protons at 5.31 ppm relative to TMS [67].
The strength of the 13C–1H dipolar coupling was measured using
the constant time dipolar coupling and chemical shift (DIPSHIFT)
experiment [68]. 1H–1H homonuclear decoupling was achieved using
the frequency-switched Lee–Goldburg (FSLG) sequence [69]. The
360° 1H pulses had a duration of 15.3 μs, yielding an effective
decoupling ﬁeld strength of 80 kHz. The MAS frequency was 7 kHz.
The signal was only acquired over one rotor period since the signal
decay induced by dipolar coupling is periodic with the rotor period.
The resulting spectra were only Fourier transformed in the direct
dimension and the dipolar dephased signal for each resolved peak
was extracted and simulated with Mathcad to obtain the dipolar
coupling. Simulations were performed for varying dipolar coupling
strengths with powder averaging in 2° increments for the β and γ
Euler angles. Other input parameters included the number of t1
increments, the dwell time and the spinning rate.
The molecular order parameters for the C\H bonds (SCH) were
calculated by dividing the measured dipolar coupling by rigid limit
values, which were obtained frommeasurements of crystalline amino
acids as reference for full dipolar coupling: CH (Ala, 13.7 kHz), CH2
(Gly, 16.3 kHz) and CH3 (Ala, 22.8 kHz) [70].
3. Results
3.1. Membrane interaction of Tau K19
The interaction of tau K19 with membranes was ﬁrst probed
using liposomes composed of PC and PS at a molar ratio of 4:1,
since membranes from AD brains have been shown to contain
signiﬁcantly higher levels of PS [71,72]. Fig. 1 shows the binding of
tau K19 to DMPC/DMPS vesicles that was detected by a change in
the intrinsic tyrosine ﬂuorescence of the protein when partitioning
into the lipid bilayer. The KD value was determined by ﬁtting the
ﬂuorescence intensities to a one-site binding model. In general, tauK19 shows a high afﬁnity for phospholipid membranes yielding a KD
of (53.3±18.3) μM for POPC, which corresponds to a protein:lipid
ratio of approximately 1:7. Not surprisingly, the binding is even
stronger for a membrane containing 20 mol% of negatively charged
PA or PS and reaches its maximum for pure DMPS (Table 1). The
nature of the phospholipid acyl chain has no observable effect on
the KD value. Furthermore, the binding afﬁnity also depends on the
ionic strength as demonstrated by a decrease of the KD at 10 mM
NaCl compared to 100 mM. These data suggest that the inter-
action of tau K19 with the lipid bilayer is mostly driven by electro-
static forces between the phospholipid headgroups and the protein,
which has a high positive charge under physiological conditions
(net charge of +7.1).
Further evidence for a membrane binding of K19 was provided
from DSC measurements using DMPC/DMPS vesicles. As expected
from the larger surface area of the PS headgroup compared to PC,
the enthalpy of the main phase transition is increased with higher
DMPS content in the absence of tau K19. However, upon adding tau
K19 the phase transition gets broadened, especially for DMPS
contents of 40 and 80% (Supplementary Fig. 1), and the transition
enthalpy is decreased in a concentration dependent manner i.e. it is
the lowest for pure DMPS (Fig. 2). This observation suggests a
preferential interaction of tau K19 with the negatively charged PS
molecules. Despite broadening of the phase transition we could not
ﬁnd a clear evidence for a lipid demixing of the membrane e.g. by
an asymmetry of the DSC traces. Only for a PC/PS ratio of 4/1 the
occurrence of the Lβ′–Pβ′ prephase transition of DMPC is observed,
which would argue for a partial demixing by tau K19 in that case.
Fig. 2. Enthalpy of the main phase transition of DMPC/DMPS LUVs with increasing
content of DMPS both in the absence (■) and in the presence of 2 mol% tau K19 ( ).
The DSC curves were recorded in buffer A. Error bars represent standard deviations of
three independent measurements.
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content was further increased.
The previous results are consistent with the detected 31P NMR
spectra of DMPC/DMPS vesicles (Supplementary Fig. 2). The spectra
show a typical powder line shape conﬁrming the liquid crystalline
lamellar bilayer structure of the membrane. The shoulder of the peak
at lower ﬁeld indicates a superposition of the spectra of both
phospholipids in the sample. By simulating the spectral line shapes
Δσ values of 44.4 ppm and 54.3 ppm were obtained and assigned to
DMPC and DMPS, respectively. In the presence of 2 mol% tau K19, the
Δσ value of DMPC is reduced by 2.8 ppm and that of DMPS by even
4.0 ppm indicating a conformational perturbation of the phospholipid
headgroups induced by the protein. This effect is again more
signiﬁcant for DMPS than for DMPC.
In contrast to thephospholipid headgroups, only a negligible inﬂuence
of tau K19 on the lipid chain conformation is found in 2H NMR
experiments. In the presence of the protein, the average order parameter
of the lipid chain is slightly increased from 0.160 to 0.163 for DMPC-d54
and from 0.173 to 0.177 for DMPS-d54 (Fig. 3a), indicating that there
is essentially no penetration of the protein into the hydrophobic core
of a DMPC/DMPS membrane. However, using vesicles consisting of
only DMPS, tau K19 clearly induces a very dramatic decrease in the
lipid chain conformational order (Fig. 3b), which can be explained byFig. 3. Smoothed 2H NMR order parameter proﬁles of the lipid methylene groups in DMPC
in 50 wt.% of buffer A (10 mM HEPES, 10 mM NaCl, pH 7.4). The temperature was 37 °C f
proﬁle for DMPC-d54 with ( ) and without (■) tau K19 and for DMPS-d54 in the presenc
( ) and with tau K19 ( ).an insertion of the protein into the acyl chain region of the bilayer.
The average order parameter for the entire lipid chain is decreased
from 0.231 in pure DMPS-d54 membranes to 0.159 in the presence of
tau K19. This loss of order leads to a reduction of the molecular
packing density and an increase in the area per DMPS molecule in
the membrane, which can be quantiﬁed according to Ref. [73]. Thus,
an increase in area per molecule of 6.5 Å2 as a consequence of tau
K19 binding was calculated.
Since it is demonstrated that tau K19 can penetrate into the lipid
bilayer, the question arises if that behavior can lead to a disruption
of the membrane integrity. Thus, we performed vesicle leakage
experiments for both DMPC/DMPS and DMPS alone. Interestingly,
tau causes a tremendous leakage of DMPS vesicles, which are
disrupted to ca. 95% by 5 mol% of the protein within 2 min
(Supplementary Fig. 3). In comparison, DMPC/DMPS vesicles show
a smaller content of leakage but 4 mol% of tau K19 still lead to 15%
leakage within 12 min (Supplementary Fig. 3). It is obvious that the
membrane disruption occurs very fast and is completed already
after a few minutes. That observation would argue for a membrane
pore formation. In contrast, a bilayer disruption caused by a
detergent-like mechanism of the protein would follow a slower,
constantly increasing kinetics.
When searching for possible lipid binding sites within tau K19,
it is reasonable that the positively charged side chains of basic
amino acids can directly interact with the negatively charged
phospholipid headgroups. Interestingly, lysine is the most frequent
amino acid residue in K19. In order to detect such binding events in
NMR experiments, the lysine ε-amino groups were 13C-methylated
by reductive alkylation [50]. Due to the natively unfolded structure
of tau K19 in solution, the lysine side chains are probably well
surface exposed. Thus, the labeling reaction went to completion as
assayed with the amino group sensitive dye ﬂuorescamine and by
mass spectrometry.
Binding contactswith themembrane, e.g. salt bridges, will change the
electronic environment of the 13C nuclei in the amino attached methyl
groups, which will consequently lead to changes in their chemical shifts.
Fig. 4 shows the 1H–13C HetCor spectra of 13C-methylated tau K19 in the
presence of DMPC andDMPC/DMPS vesicles acquired undermagic-angle
spinning (MAS) conditions. For comparison, standard 1H–13C HSQC
spectra of tau K19 in solution and after addition of 150 mM SDS are
superimposed. Most of the 13C-methyl groups cluster at one major peak
at a 1H chemical shift of 2.85 ppm and a 13C chemical shift of 39.5 ppm.
However, there are also 13CH3 signals at lower and higher ﬁeld, displaced
up to 0.8–1.4 ppm in the 1H dimension and by 1.2 ppm in the 13C/DMPS (a) and DMPS LUVs (b) in the absence and in the presence of 2 mol% tau K19
or DMPC/DMPS and 53 °C for DMPS. In (a) the curves represent the order parameter
e ( ) and in the absence ( ) of the protein. Symbols in (b) are DMPS-d54 without
Fig. 4. Contour plot of 1H–13C heteronuclear correlation (HetCor) spectra of 2 mol%
lysine Nε 13C-methylated tau K19 in complex with DMPC (black) and DMPC/DMPS
(blue) vesicles measured at 37 °C with a MAS spinning rate of 7 kHz. For comparison,
the HSQC NMR spectrum of free 13C-methylated tau K19 in solution (red) and in the
presence of 150 mM SDS (green) is indicated.
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indicating no considerable interactions of the lysine residues of tau K19
with the DMPCmembrane. However, the fact that a moderate binding is
also observed for the uncharged POPC (see Table 1), suggests that other
energetic effects contribute to tau K19 membrane binding in addition to
electrostatics. In the presence of SDS, the 13CH3 signals are slightly
downﬁeld shifted, which argues in favor of an interaction of the lysine
side chains with the micelles. When DMPC/DMPS membranes are used,
the position of the corresponding 13CH3 correlations is even more
altered. This observation further conﬁrms the involvement of lysine in
the membrane binding of tau K19. A different binding mode of the
protein in its conformationally more complex membrane environment
as compared to SDS micelles, may further explain the even more
pronounced chemical shift alterations of the 13CH3 signals in the DMPC/
DMPS membrane.3.2. Conformation of Tau K19 in a membrane environment
Using far-UV CD spectroscopy the effect of DMPC/DMPS and
DMPS vesicles on the overall conformation of tau K19 was analyzedFig. 5. Far UV CD spectra of tau K19 in buffer B (10 mMNa2HPO4, 10 mMNaCl, pH 7.4) at
37 °C. The spectra represent free tau K19 (■) and tau in the presence of 5 mM SDS ( ),
0.5 mM ( ) and 2 mM ( ) DMPC/DMPS or 0.5 mM ( ) and 2 mM ( ) DMPS.(Fig. 5). As reported previously [33], tau K19 undergoes remarkable
conformational changes in the presence of SDS micelles and lipid
vesicles. When free in solution, K19 is essentially unstructured, but
in the presence of DMPS and SDS the protein adopts signiﬁcant
α-helical structure as indicated by a lineshape change of the CD
spectra and a decrease of the ellipticity at 208 and 222 nm. This
structural change is shown to be concentration dependent and a
deconvolution of the CD spectra using the DICROWEB database
reveals the highest α-helix content for 2 mM DMPS (approximately
22%). However, a considerable content of β-sheet structure of
25–28% is also predicted from data deconvolution. It has to be
mentioned here that deconvolution of the CD data was difﬁcult due
to noise below 190 nm, which is mostly caused by light scattering
at the lipid vesicles. That is why we are careful with estimating the
exact content of secondary structure. In comparison to SDS and
DMPS, the observed conformational change is much lower for
mixed DMPC/DMPS vesicles (mol% 80:20). The lineshape of the CD
spectra is only slightly changed compared to free tau K19 and the
signals at 208 and 220 nm are much weaker than for negative
DMPS indicating no reasonable α-helical content. Since tau K19
was shown to bind DMPC/DMPS and DMPS vesicles with the same
high afﬁnity (Table 1) it is unlikely that this observation results
from an equilibrium of vesicle bound and free tau K19. Rather, it is
more likely that this represents a different protein conformation at
membranes with lower surface charge. Interestingly, deconvolution
of the CD spectra again reveals a partial β-structure content.
To further investigate the secondary structure of tau K19 in the
membrane environment at residue resolution, isotropic chemical
shifts for a selectively labeled tau K19 (with 13C labeled valine
and leucine residues) were determined by 13C solid-state MAS NMR
spectroscopy. Isotropic chemical shifts are empirically correlated to
protein secondary structure e.g. a downﬁeld shift of the 13C Cα and
CO signals compared to the random coil values and a simultaneous
upﬁeld shift of the Cβ signal indicate a helical structure. The opposite
chemical shift changes are correlated to β-sheet structures [74–76].
The isotropic 13C chemical shifts for the valine and leucine residues in
tau K19 were assigned from two-dimensional 13C–13C correlation
spectra (Fig. 6) recorded by proton driven spin diffusion (PDSD)
experiments and are summarized in Table 2. A spin diffusion time of
100 ms was used, which allows magnetization to transfer between
two 13C spin pairs separated by up to three bonds. Thus, cross peaks
occur only within a labeled amino acid and allow the assignment of
all protein signals.Fig. 6. Contour plot of 13C–13C correlation spectra of 2 mol% tau K19 in DMPC/DMPS
(black) and DMPS (blue) vesicles at a MAS spinning rate of 7 kHz. 13C–13C correlations
were established by a proton driven spin diffusion period of 100 ms. Nearest neighbor
correlations for valine (red) and leucine (yellow) are indicated. Chemical shift values
and signal assignments are given in Table 2.
Table 2
Isotropic 13C chemical shift values of tau K19 in DMPC/DMPS or DMPS membranes and corresponding protein secondary structure determined from 13C–13C correlation spectra.
1H–13C dipolar couplings (δ) and CH order parameters (SCH) were measured with the DIPSHIFT experiment.
Chemical shift (ppm) Difference
Cα–Cβ (ppm)
Secondary
structure
δ
(kHz)
SCH
Experiment Reference*
DMPC/DMPS Val 13Cα 58.4 58.0b 26.3 (25.6b) Sheet 11.6 0.85
13Cβ 32.1 32.4b 10.3 0.75
13CO 172.2 172.4b – –
Leu 13Cα 51.8 51.7b – Sheet 12.2 0.89
13CO 173.8 173.1b – –
DMPS Val 13Cα 61.6 63.0a 31.4 (33.1a) Helix 8.6 0.63
13Cβ 30.2 29.9a –d –d
13Cα 58.7 58.0b 26.6 (25.6b) Sheet 12.3 0.90
13Cβ 32.1 32.4b 11.9 0.87
13CO 173.4 173.1c Coil – –
Leu 13Cα 53.1 52.5c – Coil 9.7 0.71
13CO 175.2 176.3a (174.4c) Helix/Coil – –
*Reference values are empirical data for α-helixa, β-sheetb and random coilc conformation [104]. All chemical shifts are relative to TMS. dSignal on noise level.
Fig. 7. Proton-decoupled 188.6 MHz 13C CP MAS spectra of 2 mol% tau K19 in (b) DMPS
vesicles and (c) DMPC/DMPS membranes at a buffer content of 50 wt.% and a
temperature of 53 °C or 37 °C, respectively. The MAS spinning rate was 7 kHz. For
comparison a one dimensional spectrum for the Cα and Cβ signals of valine and leucine
based on the 13C chemical shifts of tau K19 in SDS micelles [33] is simulated in (a). A
downﬁeld shift of the Cα peak for both amino acids compared to the signals in DMPC/
DMPS membranes is indicated by arrows. Lipid signals are marked with an asterisk and
ssb denotes spinning sidebands.
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membrane samples, PDSD experiments with mixing times of 500 ms
were also performed. Correlations of longer distance could result
from intramolecular folding or from intermolecular aggregation of
the protein. However, no additional cross peaks were observed at a
mixing time of 500 ms.
In complex with DMPC/DMPS (mol% 80:20) membranes, the
chemical shifts of the individual valine and leucine carbons in all
labeled residues of tau K19 are nearly identical, i.e., no individual
residues could be identiﬁed. In each case, their peaks overlap and
no additional population for valine and leucine with a different
conformation could be observed. Furthermore, the chemical shifts
are nearly identical for two measured protein:lipid ratios of 1:50
and 1:250.
In comparison to tau K19 free in solution and in the presence
of micelles, the Cα signals of valine and leucine are upﬁeld shifted
when bound to membrane vesicles. Besides, all backbone carbon
atoms i.e. carbonyl groups and Cα atoms exhibit an upﬁeld shift
relative to empirical reference values for random coil conforma-
tion. Simultaneously, the Cβ side chain signal of valine is displaced
to lower ﬁeld. Hence, all 13C chemical shifts are indicative for a β-
sheet structure of tau K19 in its membrane environment. This
contrasts the results from solution NMR of tau K19 in the presence
of micelles [33], where the valine and leucine signals show clear
chemical shifts that are in agreement with an α-helix structure
(Fig. 7).
Since referencing of chemical shifts in solid-state NMR remains
challenging due to the lack of an appropriate internal standard, we
also analyzed the Cα–Cβ differences, which are independent of
external referencing. Thus, errors resulting from absolute chemical
shift determination can be avoided. In DMPC/DMPS membranes, the
Cα–Cβ difference for valine is 26.3 ppm, which is in good agreement
with the reference value for β-sheet structures of 25.6 ppm.
Additional information on the protein secondary structure could
be obtained from the analysis of the protein backbone and side chain
dynamics. To this end, dipolar couplings of the C\H bond vectors
were determined by the two-dimensional DIPSHIFT experiment.
Since dipolar couplings are partially motional averaged, they provide
order parameters of the amplitude of motion at the respective protein
site. Quantitative values of the dipolar coupling strength are listed in
Table 2 and were converted to molecular order parameters as
speciﬁed under Materials and methods. For both labeled amino acid
residues high order parameters of the Cα position were determined
indicating a high rigidity of the protein backbone of tau K19. In
addition, also the ﬁrst side chain position of valine shows a high
degree of order compared to other membrane-bound peptides with
β-sheet structure [70,77].Changing the DMPC/DMPS membrane to pure DMPS vesicles has
minor effects on the Cα and Cβ chemical shifts of valine. However,
the CO signal is displaced to lower ﬁeld by 1.2 ppm indicating that at
least some of the valine residues in tau K19 undergo a conforma-
tional change at the protein backbone. The chemical shift was found
to be 173.4 ppm, which is consistent to a random coil conformation
with an empirical reference value of 173.1 ppm. Furthermore,
an additional shoulder of the valine Cα cross peaks is detected in
the 13C–13C correlation spectrum. These correlations are found at
61.6 ppm and 30.2 ppm, which is close to reference values of α-
helical conformation at 63.0 ppm and 29.9 ppm. However, for most
Fig. 8. Comparison of type and location of secondary structure elements of tau K19 in
three different states: micelle-bound [33] (pink), free in solution [30] (blue) and in
PHFs [26] (green). The 13C-labeled residues, which were detected in this study, are
marked red for valine and yellow for leucine. Helices are indicated by cylinders and
β-strands are simpliﬁed by arrows.
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concluded from the intensity ratio of the corresponding cross peaks.
In contrast, the Cα and CO signals of leucine are clearly upﬁeld
shifted in comparison to tau K19 in DMPC/DMPS membranes. The
differences are 1.3 ppm and 1.4 ppm, respectively. The Cα chemical
shift (53.1 ppm) indicates a random coil whereas the CO signal of
leucine (175.2 ppm) can be classiﬁed to either α-helix or random
coil, respectively. These results suggest a structural change of tau
K19 in DMPS membranes and are in agreement with the partial α-
helical structure of K19 in the presence of negatively charged
micelles [33]. They may also reﬂect the observed differences in the
mode of interaction for two different membrane environments.
Although there are 10 labeled valine and only 6 labeled leucine
residues in tau K19, the observed conformational changes are more
clearly detectable for the leucine sites, whereas most valine residues
retain their β-structure. This observation suggests that restricted
regions within the protein may undergo a structural transformation
for instance three short patches in the center of each pseudo repeat
region, which were reported by Barré et al. [33]. In contrast, other
regions e.g. the aggregation motif PHF6 at the beginning of repeat R3
could maintain a β-structure. Noteworthy, this 9 amino acid long
sequence contains three valine residues.
In addition to isotropic chemical shifts, also dynamic information
obtained from dipolar couplings of the C\H bond vector suggests a
change of the protein secondary structure in DMPS membranes. The
order parameter of the leucine Cα atom is signiﬁcantly reduced to
0.71, which indicates a higher ﬂexibility at the protein backbone and
is consistent with a gain of α-helix structure. In contrast, the valine
residues retain a high rigidity at the Cα and Cβ positions with order
parameters of 0.90 and 0.87, which makes their location in regions of
β-structure very likely.
Since tau K19 is known to form PHFs, which exhibit signiﬁcant
β-structure, the aggregation potential of K19 in the presence of lipid
vesicles was tested using ThT ﬂuorescence. Tau ﬁlaments lead to a
large increase of the ThT ﬂuorescence at ~480 nm when excited at
450 nm, which was conﬁrmed by heparin-induced self-assembly of
tau (Supplementary Fig. 4). However, POPC/POPS and DMPC/DMPS
vesicles did not increase the ThT ﬂuorescence over the observed
time course of several days up to one week. This corresponds to the
duration of some of the NMR experiments. Thus, a ﬁlament
formation of membrane-bound tau K19 could not be detected
here. Rather, it is possible that a different type of β-structure is
formed by tau K19 in its membrane environment, for instance
smaller monomeric or oligomeric structures, which are insensitive
for ThT. They could also assemble to a pore-like structure that
would explain the membrane disruption potency of tau observed in
the leakage experiments.
4. Discussion
Understanding the pathogenic mechanisms, which lead to a
transformation of the natively unstructured protein tau into highly
ordered protein ﬁbrils is pivotal for an elucidation of its cell toxic
potential in neurodegenerative tauopathies e.g. Alzheimer's disease.
During the last decades, the contribution of several factors e.g. genetic
mutations [17–19], posttranslational modiﬁcations [78], oxidative
stress [79,80] and poly-anionic substances [11–13] in the tau
ﬁbrillization pathway has been investigated. As for other amyloido-
genic proteins, biological membranes have been suggested to be
relevant for the aggregation of tau as well [33]. The presence of
anionic detergents or lipids has been shown to greatly enhance tau
ﬁbril formation, suggesting the structure of the protein in complex
with cellular membranes to be relevant for tau aggregation and
toxicity [16]. Moreover, early tau aggregates bearing already a deci-
sive β-structure as well as mature tau PHFs have been both found to
be attached to cellular membranes and organelles [47,81].Several mechanisms could be imagined, by which lipid mem-
branes act as a template for protein misfolding and subsequent
ordering into ﬁbrils [38]. Membrane binding increases the local
protein concentration and reduces the dimensionality from three
dimensions in solution to two at the membrane surface. Thereby,
the conformational entropy could be reduced, which imparts struc-
tural ordering and leads to secondary structure formation [35]. In
that respect, biological membranes also provide a special physico-
chemical microenvironment that can inﬂuence e.g. the protonation
state of protein residues, which may also affect secondary structure
formation. Furthermore, the local solvent dielectric constant is
lowered on the membrane surface, which may facilitate the forma-
tion of intermolecular hydrogen bonds in β-sheet aggregates.
In addition, to the role of membrane binding in tau pathology,
interactions with the lipid bilayer could also be relevant for the
normal function of tau. Tau was shown to bind to the neuronal cell
membrane when expressed in PC12 cells [43,45] and it was
hypothesized that one of tau's functions may involve attaching
microtubules to membranes.
Here, we report that the three repeat domain of tau, K19, adopts a
signiﬁcant β-structure upon binding to membrane vesicles composed
of DMPC and DMPS at a molar ratio of 4:1. The chemical shifts of the
measured valine and leucine residues are consistent with reference
values for those amino acids in β-sheets. In addition, the order
parameters indicate a high rigidity of the protein backbone and of the
ﬁrst side chain position, which is typical for amino acids in ordered
ﬁbrillar β-strands [82]. The 13C-labeled valine and leucine residues
are located mainly in the ﬁrst half of each repeat region especially in
the case of repeat R3 (Fig. 8). The sequence 306VQIVYKPV313 for
instance comprises three valine residues and contains the so-called
PHF6 aggregation motif [23]. This motif has been shown to adopt a
strand-like conformation in the free state of tau [30,34] and makes up
the protease resistant core of PHFs [25,26]. It is known to play a key
role in nucleating tau ﬁlament formation. Furthermore, the successive
sequence motif 314DLSKVTSK320 was also shown to be crucial for tau
ﬁbrillization [83] and exists in a β-structure in the core of PHFs as
well [26]. Finally, also the region 337VEVKSEKLD345 at the beginning
of repeat R4 exhibits a strand-like conformation in the free state of
tau [30,31]. Hence, β-structure elements in membrane-bound tau
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tau K19. Also, an elongation of the strand regions in a similar way
as in the core structure of K19 PHFs [26] is possible. Interestingly,
based on the isotropic chemical shifts we found no evidence for an
α-helix structure of tau K19 upon binding to DMPC/DMPS
membranes. In contrast, a different lipid environment, i.e. anionic
DMPS vesicles, induces a conformational change of the protein
towards random coil and partially α-helix, which is more pro-
nounced for leucine and less signiﬁcant for valine. That structure of
tau K19 in complex with anionic phospholipids could resemble the
micelle-bound state of the protein [33] comprising three helical
patches within the center of each pseudo repeat region. It is
possible that the chemical shift changes are more important for
leucine since these residues may be located within the helix regions
whereas the valine residues reside in regions of β-structure e.g.
the PHF6 aggregation motif in repeat R3 or the 337VEVKSEKLD345
sequence at the beginning of R4 (Fig. 8). Furthermore, it is known
that Cβ-branched amino acids like threonine, valine, or isoleucine
have an intrinsic preference to be located in β-strands in the middle
of β-sheets [84,85], even though β-structure formation is deter-
mined also in large part by tertiary contacts.
Based on the available structural data a two-state model for the
interaction of tau K19 with phospholipid membranes can be pro-
posed (Fig. 9). In mixed DMPC/DMPS membranes the protein adopts
a rigid β-structure with small amplitude motions. It strongly binds
to the bilayer surface and does not penetrate into the acyl chain
region leaving the 2H quadrupolar splitting of the fatty acid chains
unchanged. Furthermore, a reduction of the 31P NMR chemical shift
anisotropy indicates a perturbation of the electronic environment of
the phosphate head groups that is introduced by tau K19. Accord-
ingly, raising the pH value or decreasing the content of negatively
charged phospholipids is believed to lower the membrane binding
since the interaction with tau K19 is mostly driven by electrostatic
interactions as shown by changes in the chemical shift for the 13C-
methylated lysine side chains.
In DMPS membranes, K19 adopts a different conformational state
that is characterized by a higher content of random coil and α-helix
structure (Fig. 9). This state could be similar to the micelle-bound
form of tau K19. Along with the observed structural change a
redistribution of the protein into the acyl chain region of the bilayer
occurs, which is indicated by a decrease of the lipid 2H order param-
eter proﬁle and causes membrane disruption as seen by an immediate
vesicle leakage. This observation is quite surprising because of the
highly charged and polar nature of tau K19. There are no obvious
hydrophobic patches in the tau sequence that would support
membrane penetration. However, a membrane-associated α-helix
can lead to a reduction in the partitioning free enthalpy of each
peptide bond by 0.5 kcal/mol due to the formation of a stable
intramolecular hydrogen bond [55]. Thus, a membrane penetration
for short helical patches of K19 could be possible. In that case, both
mechanisms i.e. membrane binding and secondary structure forma-
tion could facilitate one another.Fig. 9. Proposed structural model of tau K19 in complex with phospholipid membrane
experiments. Tau K19 adopts a rigid β-structure (blue) with small amplitude motions an
conformational change towards random coil and α-helix (orange) in certain parts of the prThe preference of forming helical intermediate structures during
the aggregation process has been found for other amyloidogenic and
antimicrobial peptides as well [38]. Depending on the relative
peptide-to-lipid concentration, Aβ [86–88], IAPP [89–91] and α-
synuclein [92–94] have been shown to shift to an α-helix structure
upon membrane binding, which then further proceeds into ﬁbril
formation. The anchoring of aggregation-prone peptides to the
membrane surface will enhance the local protein concentration,
which favors switching to a β-structure and eventually seeding of
protein ﬁbrillization. A similar role of a transiently populated helical
state of tau K19 could be imagined as well. On the other hand, a
helical conformation was not found for K19 in DMPC/DMPS vesicles,
which have a physiologically more realistic content of acidic
phospholipids. It is possible that the DMPC/DMPS membrane favors
a conversion process of an initially helical structure similar to that
seen for DMPS. Alternatively, it may be that in the DMPC/DMPS
context tau K19 maintains and possibly extends those regions with
β-structure, which are already adopted by the soluble protein.
Contacts with the bilayer surface may further stabilize the protein
structure and can assist interactions between neighboring tau mole-
cules, which could stabilize and explain the observed β-structure.
A second characteristic that tau may share with other amyloido-
genic proteins is the ability to disrupt the membrane barrier function.
A channel activity was seen for Aβ [95,96], IAPP [97], α-synuclein
[98], polyglutamine [99] and prion-derived peptides [100] which is a
strong argument for a pore formation by those proteins. In addition a
membrane thinning and disintegrating effect simultaneous to ﬁbril
growth is discussed for IAPP as well [101,102]. In our cases the rapid
kinetics of vesicle leakage strongly argues for a pore formation by tau
K19. Since within the time span of leakage no tau ﬁbrils were
observed, ﬁbrillization seems not a necessary factor for membrane
disruption but rather a monomeric or oligomeric species has to be
considered the disruptive species.
Thus, the question of the type of β-structure of K19 in its par-
ticular membrane environment arises. Several experimental ﬁndings
in this study argue against a ﬁbril structure of tau K19 in the
presence of DMPC/DMPS membranes. First, no increase in the ThT
ﬂuorescence was observed when incubating the protein together
with DMPC/DMPS or POPC/POPS liposomes for several days at 37 °C.
Secondly, there was no change in the isotropic chemical shifts as a
function of the protein–lipid ratio, even at a very high dilution of
one protein per 250 lipid molecules. If aggregation had occurred at
high protein concentrations, structural changes had likely been
caused during that process. Finally, no additional cross peaks in the
PDSD spectrum were observed when the experiment was carried
out at a longer mixing time of 500 ms. Further correlations could
arise from long range couplings e.g. between valine and leucine that
could indicate a compact monomeric or oligomeric structure. How-
ever, contacts might also occur only between amino acids of the
same type and hence may be missed in the spectrum unless indi-
vidual residues could be resolved. Therefore, structural conclusions
should not be made on the basis of missing cross-peaks alone.s that is consistent with the structural constraints obtained from solid-state NMR
d is bound to the water membrane interface. In PS membranes K19 can undergo a
otein accompanied by a redistribution into the acyl chain region of the bilayer.
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range interactions between structural elements within membrane-
bound tau K19 or between different tau molecules. Apart from a
monomeric species, another possible state of membrane-bound tau
K19, that is consistent with our data, are tau oligomers. Those
complexes possess a signiﬁcant amount of β-structure but are
insensitive to ThT or Congo red, consistent with our observations in
DMPC/DMPS. Recently, tau oligomers have emerged as the patho-
genic species in tauopathies and were hypothesized as possible
mediators of Aβ toxicity in AD [103]. It could be speculated if tau
oligomers could execute their cell toxic potential by perturbing the
barrier function of the cell membrane e.g. by a perforation of the
membrane as suggested by our observations of vesicle leakage.
Therefore, further analysis is needed to clarify the intra- as well as
intermolecular topology of membrane-bound tau K19 and to assess
its relevance for tau aggregation and toxicity in AD.
5. Conclusion
The given study provides the ﬁrst insights into the structure of
the membrane-bound state of tau K19. The protein was shown to
have a certain propensity towards zwitterionic membranes, which
is much increased in the presence of negatively charged lipids. An
interaction between lipid headgroups and lysine sidechains of the
protein could be observed. In PC/PS mixtures, a predominantly
β-sheet-like secondary structure of tau K19 at the membrane
surface has been found. The membrane senses the binding of the
protein mostly in the headgroup region as detected by 31P NMR
spectroscopy. In contrast, no signiﬁcant alterations of the membrane
packing have been observed. In a purely negatively charged mem-
brane, also α-helical secondary structure elements have been found.
Those conformational changes were associated with a deeper pene-
tration of tau K19 into the membrane. A signiﬁcant alteration of the
membrane structure was shown by a decrease in the 2H lipid chain
order parameter and by tau's membrane permeabilizing potency for
DMPS vesicles. In both membrane environments, the secondary
structure elements are relatively rigid showing little conformational
ﬂexibility. Our results support a potential role of phospholipid
membranes for the physiological and pathological functions of tau.
Supplementary data related to this article can be found online at
doi:10.1016/j.bbamem.2012.03.019.
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